Hospitalized patients with alcohol-associated hepatitis face a significantly higher risk of death if they actively use cannabis.
RT’s Three Key Takeaways:
- Elevated Mortality Risk: Patients hospitalized for alcohol-associated hepatitis who actively use cannabis face a two-and-a-half times higher mortality rate than nonusers, according to findings published in Alcohol: Clinical and Experimental Research.
- Independent Risk Predictor: Even after adjusting for underlying liver disease severity, active substance use, especially cannabis use, independently predicted patient death.
- Target for Clinical Intervention: Study authors recommend integrating routine substance use assessment and treatment into clinical healthcare protocols to inform patient prognosis and guide management.
Individuals hospitalized with alcohol-associated hepatitis are significantly more likely to die from the condition if they use cannabis, according to a multinational study published in Alcohol: Clinical and Experimental Research.
The investigation is the first to identify active substance use, particularly cannabis use, as an independent predictor of mortality in patients diagnosed with alcohol-associated hepatitis.
Alcohol-associated hepatitis is a severe form of liver damage driven by alcohol consumption that can rapidly progress to acute organ failure and death. Nearly half of individuals with severe forms of the disease die within 90 days, and mortality rates continue to rise in the US, particularly among women and younger adults.
To evaluate the prognostic impact of concurrent drug use, researchers followed 800 patients hospitalized for alcohol-associated hepatitis across 40 medical centers located in 13 countries. Among the cohort, 6% (50 patients) reported active cannabis use, 45 patients reported cocaine use, and less than 2% reported using methamphetamine, opioids, or other substances.
At approximately 80 days following intake, one-quarter of all hospitalized patients had died. Active cannabis and cocaine use were significantly more frequent among patients presenting with severe hepatitis.
Statistical analysis demonstrated that even after controlling for baseline liver disease severity, active substance use independently predicted patient mortality. Active cannabis users demonstrated a two-and-a-half times higher mortality rate relative to individuals who did not report active use.
Based on the data, the authors concluded that active substance use should serve as a primary target for clinical intervention in patients with alcohol-associated liver disease. The researchers recommend that inpatient healthcare teams routinely incorporate standardized substance use evaluations into ongoing care protocols to better anticipate clinical trajectories and refine treatment planning.
